• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内分泌疾病继发糖尿病:诊断和治疗特点的更新。

Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.

机构信息

Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410073 Oradea, Romania.

Bihor County Emergency Clinic Hospital, 410167 Oradea, Romania.

出版信息

Int J Mol Sci. 2023 Aug 11;24(16):12676. doi: 10.3390/ijms241612676.

DOI:10.3390/ijms241612676
PMID:37628857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10454882/
Abstract

Secondary diabetes mellitus is frequently ignored in specialized literature. In this narrative review, the main endocrinopathies accompanied by increased glycemic values are identified, as well as the mechanisms by which the excess or deficiency of certain hormones impact beta cell function or insulin resistance. The main endocrinopathies (acromegaly, Cushing's syndrome, Basedow-Graves' disease, pheochromocytoma, somatostatinoma and glucagonoma) and their characteristics are described along with the impact of hormone changes on blood sugar, body mass index and other parameters associated with diabetes. The overall information regarding the complex molecular mechanisms that cause the risk of secondary diabetes and metabolic syndrome is of crucial importance in order to prevent the development of the disease and its complications and particularly to reduce the cardiovascular risk of these patients. The purpose of this study is to highlight the particular features of endocrine pathologies accompanied by an increased risk of developing diabetes, in the context of personalized therapeutic decision making. The epidemiological, physiopathological, clinical and therapeutic approaches are presented along with the importance of screening for diabetes in endocrine diseases.

摘要

继发性糖尿病在专业文献中经常被忽视。在本综述中,确定了伴随血糖升高的主要内分泌病变,以及某些激素过多或缺乏如何影响β细胞功能或胰岛素抵抗的机制。描述了主要的内分泌病变(肢端肥大症、库欣综合征、格雷夫斯病、嗜铬细胞瘤、生长抑素瘤和胰高血糖素瘤)及其特征,以及激素变化对血糖、体重指数和其他与糖尿病相关参数的影响。了解导致继发性糖尿病和代谢综合征风险的复杂分子机制非常重要,这有助于预防疾病及其并发症的发生,特别是降低这些患者的心血管风险。本研究旨在突出伴有糖尿病发病风险增加的内分泌病变的特殊特征,以便在制定个体化治疗决策时参考。本文介绍了流行病学、病理生理学、临床和治疗方法,以及在内分泌疾病中筛查糖尿病的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/b288b0beacb1/ijms-24-12676-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/8480fac5e26a/ijms-24-12676-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/80abff6289be/ijms-24-12676-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/a27dfd4f39f4/ijms-24-12676-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/ee50572363e8/ijms-24-12676-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/b288b0beacb1/ijms-24-12676-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/8480fac5e26a/ijms-24-12676-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/80abff6289be/ijms-24-12676-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/a27dfd4f39f4/ijms-24-12676-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/ee50572363e8/ijms-24-12676-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f152/10454882/b288b0beacb1/ijms-24-12676-g005.jpg

相似文献

1
Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.内分泌疾病继发糖尿病:诊断和治疗特点的更新。
Int J Mol Sci. 2023 Aug 11;24(16):12676. doi: 10.3390/ijms241612676.
2
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.与主要内分泌疾病相关的继发性糖尿病:新治疗模式的影响
Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26.
3
[Diabetes mellitus secondary to an endocrine pathology : when to think about it ?].[内分泌疾病继发的糖尿病:何时应考虑?]
Rev Med Suisse. 2017 May 31;13(565):1158-1162.
4
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.库欣综合征、肢端肥大症和神经内分泌肿瘤继发糖尿病的实用治疗方法。
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
5
A case of acromegaly accompanied by adrenal preclinical Cushing's syndrome.一例肢端肥大症伴肾上腺亚临床库欣综合征。
Endocr J. 1999 Feb;46(1):133-7. doi: 10.1507/endocrj.46.133.
6
Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease.曾接受肢端肥大症或库欣病治疗的垂体功能减退患者的生长激素缺乏与替代治疗
Eur J Endocrinol. 2002 Jan;146(1):67-74. doi: 10.1530/eje.0.1460067.
7
[Insulin resistance in pituitary, thyroid, and adrenal diseases].[垂体、甲状腺及肾上腺疾病中的胰岛素抵抗]
Nihon Rinsho. 2000 Feb;58(2):451-5.
8
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management.肢端肥大症患者的糖尿病:病理生理学、临床挑战与管理
Nat Rev Endocrinol. 2024 Sep;20(9):541-552. doi: 10.1038/s41574-024-00993-x. Epub 2024 Jun 6.
9
Insulin resistance in endocrine disorders - treatment options.内分泌疾病中的胰岛素抵抗——治疗选择
Endokrynol Pol. 2017;68(3):334-351. doi: 10.5603/EP.2017.0026.
10
[Diabetes and prediabetes in endocrine disorders].[内分泌疾病中的糖尿病和糖尿病前期]
Wiad Lek. 2012;65(3):187-98.

引用本文的文献

1
Optimized buccoadhesive repaglinide-loaded cubogel: In-vitro characterization and in-vivo hypoglycemic activity in a streptozotocin-induced diabetic rat model.优化的载瑞格列奈口腔黏附立方凝胶:链脲佐菌素诱导的糖尿病大鼠模型中的体外表征及体内降血糖活性
Int J Pharm X. 2025 Jul 14;10:100357. doi: 10.1016/j.ijpx.2025.100357. eCollection 2025 Dec.
2
Awareness of Risk Factors for Type-2 Diabetes Mellitus among Undergraduates at a Private University in Nigeria: A Cross-Sectional Survey.尼日利亚一所私立大学本科生对2型糖尿病危险因素的认知:一项横断面调查。
Rwanda J Med Health Sci. 2024 Nov 30;7(3):495-505. doi: 10.4314/rjmhs.v7i3.10. eCollection 2024 Nov.
3

本文引用的文献

1
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.GLP-1 激动剂在肥胖中的新作用:随机对照试验的综合综述。
Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449.
2
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.解锁 SGLT2 抑制剂的全部潜力:超越血糖控制的应用拓展。
Int J Mol Sci. 2023 Mar 23;24(7):6039. doi: 10.3390/ijms24076039.
3
How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.
Multitarget neuroprotective effects of β-sitosterol in diabetes-associated neurodegeneration: a coupled experimental/computational study.
β-谷甾醇在糖尿病相关性神经退行性变中的多靶点神经保护作用:一项实验与计算相结合的研究
J Comput Aided Mol Des. 2025 Jun 14;39(1):30. doi: 10.1007/s10822-025-00609-0.
4
Increased risk of multisystem comorbidities and disease trajectories following hyperthyroidism: evidence from the 0.5 million UK Biobank population.甲状腺功能亢进症后多系统合并症和疾病轨迹风险增加:来自英国生物银行50万人群的证据。
Endocr Connect. 2025 Apr 23;14(5). doi: 10.1530/EC-25-0066. Print 2025 May 1.
5
Nomogram for predicting postoperative clinical remission of hypertension in patients with adrenal tumors.预测肾上腺肿瘤患者术后高血压临床缓解的列线图
Discov Oncol. 2025 Mar 17;16(1):341. doi: 10.1007/s12672-025-02108-y.
6
Importance of etiologies of secondary diabetes: How often do we think off in clinical practice?继发性糖尿病病因的重要性:在临床实践中我们多久会思考一次?
World J Clin Cases. 2025 Feb 16;13(5):95879. doi: 10.12998/wjcc.v13.i5.95879.
7
Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor.抗糖尿病药物的内分泌反应分析:钠-葡萄糖协同转运蛋白2抑制剂导致血浆肾素浓度升高的问题
Int J Gen Med. 2025 Jan 11;18:135-144. doi: 10.2147/IJGM.S497664. eCollection 2025.
8
Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.基因型阴性的1型多发性内分泌腺瘤病伴泌乳素瘤、甲状旁腺功能亢进和亚临床库欣综合征并伴有高血糖:病例报告
Front Endocrinol (Lausanne). 2024 Dec 12;15:1498991. doi: 10.3389/fendo.2024.1498991. eCollection 2024.
9
Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.肢端肥大症和库欣病中糖尿病的管理:聚焦帕西瑞肽治疗的叙述性综述
Diabetes Metab Syndr Obes. 2024 Jul 23;17:2761-2774. doi: 10.2147/DMSO.S466328. eCollection 2024.
10
Imaging abnormalities of the pancreas in diabetes: implications for diagnosis and treatment.糖尿病患者胰腺的影像学异常:对诊断和治疗的影响。
Curr Opin Gastroenterol. 2024 Sep 1;40(5):381-388. doi: 10.1097/MOG.0000000000001054. Epub 2024 Jun 28.
如何在肢端肥大症患者的糖尿病管理中定位钠-葡萄糖协同转运蛋白2抑制剂。
Endocrine. 2023 Jun;80(3):491-499. doi: 10.1007/s12020-023-03352-4. Epub 2023 Mar 31.
4
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023.2. 糖尿病的分类和诊断:2023 年糖尿病护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S19-S40. doi: 10.2337/dc23-S002.
5
Diagnosis and Treatment of Acromegaly: An Update.肢端肥大症的诊断与治疗:最新进展。
Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007.
6
The Effect of Curative Treatment on Hyperglycemia in Patients With Cushing Syndrome.治疗对库欣综合征患者高血糖的疗效
J Endocr Soc. 2021 Dec 2;6(1):bvab169. doi: 10.1210/jendso/bvab169. eCollection 2022 Jan 1.
7
Risk of Diabetes in Patients with Long-Standing Graves' Disease: A Longitudinal Study.长期Graves 病患者发生糖尿病的风险:一项纵向研究。
Endocrinol Metab (Seoul). 2021 Dec;36(6):1277-1286. doi: 10.3803/EnM.2021.1251. Epub 2021 Dec 16.
8
Consensus on diagnosis and management of Cushing's disease: a guideline update.库欣病的诊断和治疗共识:指南更新。
Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20.
9
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.格雷夫斯甲状腺和甲状腺外疾病的管理:更新。
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
10
Glucagonoma: From skin lesions to the neuroendocrine component (Review).胰高血糖素瘤:从皮肤病变到神经内分泌成分(综述)
Exp Ther Med. 2020 Oct;20(4):3389-3393. doi: 10.3892/etm.2020.8966. Epub 2020 Jul 3.